Plain-English translation of NCT07363577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study is testing a new medication called LB-102 to see if it can help adults who are experiencing an acute (sudden) worsening of schizophrenia symptoms. Researchers want to find out if the medication works better than a placebo (a pill with no active ingredient) and to understand how safe it is. The study will compare two different doses of the medication against placebo.
Schizophrenia can cause sudden, severe symptoms that are difficult to manage, and doctors need more treatment options. This trial is designed to see if this medication offers a new, effective choice for people experiencing these acute episodes.
You likely qualify if…
You likely don't qualify if…
You would stay in the hospital for 6 weeks and take either a dose of LB-102, a different dose of LB-102, or a placebo pill once daily by mouth. Neither you nor the researchers would know which treatment you're receiving (this is called being 'blinded'). During your stay, the study team would regularly check how you're doing through symptom assessments, blood tests, and safety monitoring to see how the medication affects you.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States